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This article reports the current evidence and expert opinions on the diagnosis and management of
neurogenic lower urinary tract dysfunction (NLUTD) in Taiwan. The main problems of NLUTD are failure
to store, failure to empty, and a combination of these two. Priorities in the management of NLUTD, in
order of importance, should be the following: (1) preservation of renal function; (2) freedom from
urinary tract infection; (3) efﬁcient bladder emptying; (4) freedom from indwelling catheters; (5) patient
agreement with the management modality; and (6) avoidance of medication after proper management.
Management of the urinary tract in patients with spinal cord injuries or multiple sclerosis must be based
on urodynamic ﬁndings rather than on inferences from the neurological evaluation. Identiﬁcation of
high-risk patients is important to prevent renal functional impairment in those with chronic NLUTD. The
lower urinary tract function of patients with NLUTD should be regularly followed up by urodynamic
study, and any urological complication should be treated adequately. Avoiding a chronic indwelling
catheter can reduce the incidence of developing a low compliant bladder. Intravesical instillation of
vanilloids and injecting botulinum toxin-A are alternative treatments for refractory detrusor overactivity
or a low compliant bladder, and can replace the need for bladder augmentation. When surgical inter-
vention is necessary, less invasive types of surgery and reversible procedures should be considered ﬁrst,
and any unnecessary surgery in the lower urinary tract should be avoided. Keeping the bladder and
urethra in good condition without the interference of neuromuscular continuity provides patients with
NLUTD the opportunity to use new technologies in the future. Improving the quality of life in patients
with neurogenic voiding dysfunction is the most important aspect of treatment.
Copyright © 2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.uddhist Tzu Chi General Hospital, 707, Section 3, Chung-Yang Road, Hualien, Taiwan. Tel.: þ886 3 8561825x2117;
elief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
H.-C. Kuo et al. / Tzu Chi Medical Journal 26 (2014) 103e1131041. Introduction lesions: traumatic, vascular, medical, or congenital [25e27]. (9)Neurogenic lower urinary tract dysfunction (NLUTD) includes
dysfunction of the urinary bladder and urethra due to lesions of the
central nervous system or peripheral neurogenic lesions. Cerebro-
vascular accidents (CVAs), intracranial lesions, Parkinson's disease
(PD), cerebral palsy, multiple sclerosis (MS), transverse myelitis,
and spinal cord lesions can result in NLUTD [1]. Spinal cord injury
(SCI) and MS remain the most difﬁcult to manage disorders causing
NLUTD.
Frequency, urgency, and urinary incontinence are all commonly
reported in patients with neurogenic detrusor overactivity (NDO).
Approximately 10% of patients with stroke develop neurogenic
disease [2]. Up to 75% of MS patients report some form of urinary
incontinence [3]. One in 10 patients presents with bladder symp-
toms at the time of MS diagnosis [4]. The vast majority of SCI pa-
tients have bladder dysfunction [5].
NLUTD presents a great disease burden on patients, affecting not
only their prognosis but also their quality of life (QoL), self-esteem,
and relationship with their families. It is commonly associated with
urinary incontinence, voiding problems, reduction in bladder
compliance, and upper urinary tract damage [6].
Priorities in the management NLUTD, in order of importance,
should be the following: (1) preservation of renal function; (2)
freedom from urinary tract infection (UTI); (3) efﬁcient bladder
emptying; (4) freedom from indwelling catheters; (5) patient
agreement with the management modality; and (6) avoidance of
medication after proper management. As the diagnosis and man-
agement of NLUTD are complex, guidelines for clinical practice in
the treatment of patients with NLUTD are mandatory.2. Purpose
The purpose of these clinical guidelines is to provide informa-
tion on the incidence, deﬁnitions, diagnosis, therapy, and follow-up
observation of patients with NLUTD. These guidelines may be
useful for physicians and patients in the management of NLUTD.3. Terminology
The following abbreviations are used throughout these guide-
lines: AD, autonomic dysreﬂexia; DA, detrusor areﬂexia; DSD,
detrusor sphincter dyssynergia; DU, detrusor underactivity; NDO,
neurogenic detrusor overactivity; NLUTD, neurogenic lower uri-
nary tract dysfunction; NVD, neurogenic voiding dysfunction; SCI,
spinal cord injury.
Other terminology follows the recommendations of the Inter-
national Continence Society [7,8].4. Etiology of NLUTD
NLUTD may be caused by various diseases and events affecting
the nervous systems controlling the lower urinary tract. NLUTD
should be considered in patients with sudden onset of lower uri-
nary tract symptoms (LUTSs) such as acute urinary retention or
urge urinary incontinence (UUI). The following are possible etiol-
ogies of NLUTD. (1) Peripheral neuropathy: diabetes [9], alcohol
abuse [10], and herpes zoster [11]. (2) Latrogenic: abdominoper-
ineal resection of the rectum or uterus [12,13]. (3) Demyelinization:
MS [14e16]. (4) Dementia: Alzheimer, Binswanger, Nasu, and Pick
diseases [17e19]. (5) Basal ganglia pathology: PD, Huntington dis-
ease, and ShyeDrager syndrome [20,21]. (6) Cerebrovascular pa-
thology [22,23]. (7) Frontal brain tumors [24]. (8) Spinal cordDisc disease [28,29]. (10) Regional spinal anesthesia [30].
5. Epidemiology of SCI in Taiwan
The incidence of SCI worldwide, as reported in the literature,
ranges from 12.1 per million to 57.8 per million [31]. Bladder
dysfunction occurs depending on the level and location of the SCI
[32]. The most common etiologies of SCI are motor vehicle crash
injuries in patients under 60 years of age and falls in those older
than 61 years [33].
A study of the prevalence and incidence of NDO from SCI in
Taiwan during 2006e2008 revealed an overall 3-year prevalence
rate of 855 per million and an incidence rate of 241 per million
person-years, which were similar to a previous study (246 per
million person-years) andmuch higher than those in Japan (124 per
million person-years), Canada (53 per million person-years), and
the USA (40 per million person-years, 59 per million person-years)
[34]. The frequency of NDO was around 16.9% in SCI patients with
transient urinary incontinence and 17.5% in those with permanent
NDO. Among all SCI patients, 82% with SCI and NDO used cathe-
terization with (46%) or without (36%) pharmacological treatment.
Patients with SCI and NDO have more expenses for hospitalization
than those without NDO. This has a great impact on the ﬁnancial
burden of health insurance.
6. Clinical symptoms and urodynamic ﬁndings in NLUTD
patients
6.1. Cerebral vascular diseases
The clinical symptoms of NLUTD depend on the levels of lesions
[35]. With lesions above the brain stem, involuntary bladder con-
tractions with sphincter synergy and preserved bladder sensation
can occur, and NDO is likely to develop. Urinary incontinence is the
most common problem in the acute phase (within 3 months post
CVA). The degree of incontinence declines over time. However,
other voiding issues might appear. LUTSs, especially storage
symptoms such as frequency and urgency with or without UUI,
commonly present in the chronic phase (3 months post CVA)
[23,36,37].
Because most menwith CVAs are elderly, other pathophysiology
that causes male LUTSs, such as bladder outlet obstruction, might
confuse the diagnosis and treatment of voiding dysfunction in them
[38,39]. However, patients with chronic CVAs may have both
detrusor overactivity (DO) and uninhibited relaxation of the ure-
thral sphincter causing urinary incontinence [40,41]. Detrusor un-
deractivity (DU) and detrusor hyperactivity with impaired detrusor
contractility might be other problematic issues in elderly patients
with multiple CVAs or those in the acute phase [42,43].
Urethral sphincter pseudodyssynergia may develop in about
10% of patients during the recovery phase (4e10 months post CVA)
[42,43]. Urethral sphincter pseudodyssynergia is characterized by
voluntary contraction of the external sphincter during involuntary
detrusor contractions [44]. Patients might have LUTSs such as
difﬁcult urination, slow stream, and incomplete bladder emptying.
6.2. Parkinson's disease
PD is the second most common neurodegenerative disease after
Alzheimer's disease [45], affecting 1 million people each year in the
United States [46]. More than 270,000 people in Taiwan have Par-
kinson's syndrome, and among them 40,000 have PD [47]. PD is a
multisystem disorder involving the dopaminergic, noradrenergic,
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motor and nonmotor symptoms [48].
A large proportion of patients with PD present with urinary
dysfunction including urgency, increased frequency, or inconti-
nence as predominant symptoms [49]. Urinary symptoms are sta-
tistically correlatedwith the severity of the disease but not with the
duration of illness, and no sexual differences have been noted [50].
The presence of voiding dysfunction in parkinsonian patients has
been reported in several studies, with an incidence of 37e71% [19].
Voiding dysfunction occurs when the extrapyramidal system is
damaged, such as in PD.
A previous investigation showed that 40e70% of parkinsonian
patients have some degree of voiding dysfunction, and nearly 70%
of them have irritative symptoms [51]. DO was the predominant
urodynamic ﬁnding, which may explain the LUTSs in patients with
PD. Pseudodyssynergia occurs in 25e60% of parkinsonian patients
[51]. Patients with PD and a hyperactive urethral sphincter may not
be able to adequately relax their urethral sphincter during voli-
tional or reﬂexic micturition, resulting in inadequate detrusor
contractility and an increased postvoid residual (PVR) [52].
6.3. Spinal cord injury
Spinal cord lesions can be traumatic, vascular, medical, or
congenital. The incidence in the USA is 30e40 new cases per
million of the population. Most patients develop NLUTD [53]. A
high correlation exists between the clinical neurological ﬁndings
and NLUTD in single-level traumatic spinal cord lesions, but not in
myelomeningocele and combined traumatic spinal cord lesions
[54,55]. In SCI lesions above T6, patients may have smooth muscle
dyssynergia and autonomic dysreﬂexia (AD) in addition to detrusor
sphincter dyssynergia (DSD).
SCI patients may have LUTSs such as urgency and UUI. Some
patients with bladder neck dysfunction and DSD may also experi-
ence difﬁculty in bladder emptying and urinary retention [56e58].
Usually in patients with a complete spinal cord lesion at the T6eS2
levels, involuntary bladder contractions without sensation and DSD
develop [59]. In most patients with spinal cord lesions below S2,
detrusor areﬂexia (DA) with retained residual urethral sphincter
tone not under voluntary control will cause difﬁcult urination.
Patients have to urinate by abdominal straining, the Crede ma-
neuver, or clean intermittent catheterization (CIC) to empty the
bladder [60]. Patients with low urethral sphincter tone may also
have urinary incontinence. Interruption of the peripheral reﬂex arc
will cause DA and low bladder compliance, which results in
incomplete bladder emptying and may also endanger the upper
urinary tract. Spinal biﬁda and other congenital nerve tube defects
are also prevalent in the 25e29-year age group, and half of these
patients have DSD [61,62].
A survey indicated that improving bladder dysfunction, bowel
dysfunction, and AD were among the seven highest priorities of SCI
patients with paraplegia and tetraplegia [63]. As patients with SCI
consider urinary incontinence inevitable after injury, many pa-
tients self-manage by decreasing ﬂuid intake, voiding frequently,
and wearing pads. Patients can be symptomatic for years prior to
seeking treatment [64]. A physician's assessment of the disease
burden can be inaccurate and nonreproducible [65]. When the
problem is reported, many physicians fail to evaluate the condition
[66]. Most physicians would like to treat more complicated physical
conditions rather than urinary incontinence.
Neurogenic conditions are associated with a signiﬁcant reduc-
tion in QoL, and urinary incontinence can further reduce it [67].
Bladder symptoms are a leading disability in some neurogenic
patients, and are often the cause of reduced participation in work
and social activities [68]. Urinary incontinence poses a majorlimitation to sexuality in SCI patients [69]. The frequency of in-
continence has a strong inﬂuence on health-related QoL. In one
study, among all patients with SCI who had CIC by an attendant,
those with indwelling transurethral catheters and suprapubic
catheters had the worst mental status [70].
SCI patients have higher rates of depression than the healthy
population, and this is closely related to gender and the ability to
perform self-catheterization [71]. It has been estimated that <50%
of SCI patients have good knowledge about bladder management
and pressure ulcers after being discharged from the hospital. They
also are reluctant to discuss bladder symptoms with physicians and
other patients. Many clinicians believe that NDO does not affect
mortality/morbidity. In addition, SCI patients do not knowwhere or
how to avail of Medicare beneﬁts [72]. Therefore, there is a need to
increase patient awareness of the urological complications of
NLUTD and to educate physicians about treatment strategies for
NLUTD.
6.4. Multiple sclerosis
MS is a major cause of nontraumatic disability in young adults.
The total estimated prevalence is 83/100,000. It is most commonly
seen in the 35e64-years age group, with a male to female ratio of
incidence of 1:2 [73e76]. Urodynamically, DO occurs in about
44e81%, DSD in about 25%, and DU in 19e40% of patients with MS.
Up to 10% of patients have bladder dysfunction at the initial MS
diagnosis. Urodynamic studies were found to be abnormal in 50% of
asymptomatic MS patients and in 100% of symptomatic patients.
Urgency (32e86%), nocturia (25e82%), and UUI (19e80%) are
highly prevalent in MS patients; however, they may also have
dysuria (6e79.5%) and urinary retention (8.3e73.8%), depending on
the involvement of the central nervous system and chronicity of the
disease [77]. Sudden onset of LUTSs and DO or DSD, as found in
urodynamic studies, should alert the physician to MS, especially in
young adults. MS patients' attitude toward voiding management
should be respected. Patients may be bothered more by emptying
dysfunction than by bladder storage symptoms.
DO and DSD commonly occur in patients with suprasacral cord
lesions, such as those with SCI, MS, or transverse myelitis. The
presence of DSD is associated with complete injuries, elevated
intravesical pressures, and upper tract complications [55]. Patients
with DSD usually have urinary incontinence and a large PVR
requiring CIC or an indwelling Foley catheter. These urological
complications usually result in a low QoL and may cause more
serious complications such as AD, UTI, and upper urinary tract
deterioration [78].
7. Classiﬁcation of NLUTD
A perfect classiﬁcation system is not yet available. Most of the
currently used classiﬁcations of NLUTD are based on bladder and
urethral dysfunctions. Previous classiﬁcations of NLUTD included
Bors and Comarr's [79] neurourological classiﬁcation, Bradley et al's
[80] four loops neurological classiﬁcation, and Lapides' [81] and
Krane and Siroky's [82] urodynamic classiﬁcation of detrusor and
urethral sphincter dyscoordination. Wein [83] and Fall et al [84]
classiﬁed NLUTD as failure to store and failure to empty, based on
detrusor and urethral dysfunction. The International Continence
Society also separates NLUTD into detrusor and urethral dysfunc-
tion in the storage and voiding phases [8].
A clinically useful classiﬁcation of NLUTD should help physicians
manage patients. Early diagnosis and treatment are essential, as
irreversible changes may occur, in particular in children with
myelomeningocele. Individual variations exist in neurogenic void-
ing dysfunction (NVD) caused by a speciﬁc neurological lesion.
Table 1
ASIA Impairment Scale.
A¼ Complete: No motor or sensory function is preserved in the sacral segments
S4eS5.
B ¼ Incomplete: Sensory but not motor function is preserved below the
neurological level and includes the sacral segments S4eS5.
C ¼ Incomplete: Motor function is preserved below the neurological level, and
more than half of key muscles below the neurological level have a muscle
grade <3.
D ¼ Incomplete: Motor function is preserved below the neurological level, and
at least half of key muscles below the neurological level have a muscle grade
3.
E ¼ Normal: Motor and sensory functions are normal.
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tract disease (LUTD) completely. Therefore, in any particular pa-
tient, the description of NLUTD should be individualized.
The main problems of NLUTD are as follows: (1) failure to store
due to DO or urethral incompetence; (2) failure to empty due to DA,
bladder neck dysfunction, or DSD; and (3) combined failure to store
and empty due to DSD or DO and detrusor hyperactivity with
impaired detrusor contractility.
8. Classiﬁcation of SCI severity
Clinicians have long used a clinical scale to grade the severity of
neurological loss. First devised at Stoke Mandeville Hospital,
Buckinghamshire, Great Britain prior to World War II and popu-
larized by Frankel in the 1970s, the original scoring approach
segregated patients into ﬁve categories as follows: no function (A),
sensory only (B), some sensory and motor preservation (C), useful
motor function (D), and normal (E) [85].
The American Spinal Injury Association (ASIA) Impairment Scale
follows the Frankel Scale but differs from the older scale in several
important respects. First, instead of no function below the injury
level, ASIA-A indicates no motor or sensory function preserved in
the sacral segments S4e5. ASIA-B is essentially identical to Frankel
B but adds the requirement of preserved sacral S4e5 function. It
should be noted that the ASIA-A and ASIA-B classiﬁcations depend
entirely on a single observation, i.e., the preservation of motor and
sensory function of S4e5.
The ASIA Scale also added quantitative criteria for C and D cat-
egories. ASIA-C was diagnosed if more than half of the muscles
evaluated had a grade of less than 3/5. If not, the classiﬁcation was
ASIA-D. ASIA-E implies an SCI without any neurological deﬁcits
detectable on a neurological examination of this type.
The new ASIA-A categorization has been more predictive of
prognosis than the previous deﬁnition, where the presence of
function several segments below the injury site but the absence of
the function below a given level can be interpreted as an “incom-
plete” SCI.
The ASIA committee also classiﬁed incomplete SCIs into ﬁve
types. A central cord syndrome is associated with a greater loss of
upper limb function compared with the lower limbs.
BrowneSequard syndrome results from a hemisection lesion of the
spinal cord. Anterior cord syndrome occurs when the injury affects
the anterior spinal tracts, including the vestibulospinal tract. Conus
medullaris and cauda equina syndromes occur when the conus or
spinal roots of the cord are damaged (Table 1).
9. Diagnosis of NLUTD
Diagnosis of NLUTD should be based on neurological lesions and
somatic and visceral dysfunction. Medical comorbidity may alter
the LUTSs [25]. The diagnostic procedures should include the
following. (1) General history: neurological and systemic diseases.
(2) Speciﬁc history: urinary history, bowel history, sexual history,
and neurological history. (3) Physical examination: general physical
examination and neurourological examination. (4) Speciﬁc neuro-
urological examination: evaluation of sensation from S2 to S5
bilaterally, reﬂexes, anal sphincter tone, and volitional contraction
of the anal sphincter and pelvic ﬂoor. (5) Laboratory tests. (6)
Urodynamic study.
10. Urological surveillance
The goal of urological surveillance is functional (F) and
anatomical (A) assessment of the urinary tract after NLUTD. The
assessments should include the following steps. (1) Laboratory tests(F): These include urinalysis, urine culture, renal function tests, and
glomerular ﬁltration rate. (2) Intravenous pyelography (F, A): This is
useful for assessingupper tract function and anatomical changes. (3)
Renal ultrasound (A): It is used to detect hydronephrosis or renal
scarring. (4) Renal scan (F): Both dimercaptosuccinic acid (DMSA)
and diethylene triamine pentaacetic acid (DTPA) scans are neces-
sary. (5) Voiding cystourethrography (A) is required. (6) Cystoscopy
(A): For the detection of bladder trabeculation and determination of
urethral condition, cystoscopy is performed. (6) Urodynamic studies
(F): Urodynamic investigation is necessary to document the func-
tion or dysfunction of the lower urinary tract. The recording of a
bladderdiary is highlyadvisable. Freeuroﬂowmetryand assessment
of the PVR are mandatory prior to invasive urodynamics is planned.
The detrusor leak point pressure (DLPP) is an important investiga-
tion in patients with endangered upper tracts. Speciﬁc uroneur-
ophysiological tests such as electromyography of pelvic ﬂoor
muscles and the urethral sphincter, pudendal nerve conduction
velocity, and the bulbocavernous reﬂex and anal reﬂex arc latency
time are elective procedures. Fast ﬁlling cystometry with an ice
water test has been presumed to distinguish between upper and
lower motor neuron lesions [86]. A positive bethanechol test is
considered proof of detrusor denervation [87]. These are optional
tests for speciﬁc patients with NLUTD. (7) Videourodynamics (F, A):
This procedure is performed to determine bladder function and the
vesicoureteral reﬂux (VUR). Videourodynamics is the gold standard
for invasive urodynamics inpatientswithNLUTD. Videourodynamic
study can detect bladder and urethral dysfunction, as well as
morphological pathology in the lower and upper urinary tract
[7,88,89]. If this is not available, aﬁlling cystometry continuing into a
pressure ﬂow study should be performed.
11. Selecting high-risk patients
A signiﬁcant association between the level of injury and the type
of voiding dysfunction has been noted in patients with a single-
level SCI. Management of the urinary tract in patients with SCI
must be based on urodynamic ﬁndings rather than on inferences
from the neurological evaluation [57,90].
It is important to screen patients at high risk, including those
with complete neurological lesions, cervical spinal cord paraplegia,
prolonged indwelling catheter, high DLPP, DSD, AD, a large PVR, and
VUR. When the DLPP is >40 cmH2O, the upper tract is endangered
[7,91].
Correction of urological complications and improvement of QoL
with respect to urinary incontinence are the two main goals in the
management of NVD. In addition, each patient should be evaluated
for and managed with an individualized treatment strategy.
12. Treatment of NLUTD
The following should be the primary aims and priorities in the
treatment of NLUTD: (1) protection of the upper urinary tract; (2)
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tient's QoL; (4) restoration of (parts of) normal lower urinary tract
function; and (5) further considerations such as patients' disability,
cost effectiveness, technical intricacy, and possible complications.
The ﬁrst aim of any therapy is protection of the upper urinary
tract and reduction of mortality from urological complications in
patients with NLUTD [25,56,92e99].
The mainstay of treatment for an overactive detrusor is anti-
cholinergic drug therapy. Rehabilitation and neuromodulation may
be effective in selected cases. A condomcatheter or padsmay reduce
incontinence to a socially acceptable level. Any method of assisted
bladder emptying should be used with the greatest caution.
The main goals of treatment of NLUTD are as follow: (1)
correction of urinary tract complications including hydronephrosis,
VUR, UTI, and a contracted bladder; (2) lowering storage intra-
vesical pressure, and controlling or alleviating symptoms
(including incontinence and difﬁcult urination) [60]; and (3)
improving QoL with respect to urinary incontinence, treating uri-
nary incontinence and difﬁcult urination, improving bladder
emptying, and avoiding indwelling catheters and UTI [96,97]. It is
difﬁcult to estimate the vesicourethral dysfunction based on the
level of an SCI. Therefore, a videourodynamic study or pressure ﬂow
study combined with voiding cystourethrography is necessary to
identify detrusor and sphincter dysfunction. An individual strategy
for each NLUTD patient is mandatory.
12.1. Noninvasive conservative management of NLUTD
Conservative management is the mainstay of urological treat-
ment for NVD, if possible. Patients can be instructed to void by
abdominal stimulation (triggered reﬂex voiding), the Crede ma-
neuver, or abdominal straining (Valsalva) [100,101]. If they do not
have a balanced bladder after training, CIC, either by themselves or
by a caregiver, is necessary [102e104]. Spontaneous voiding with
and without triggered voiding and/or bladder expression has been
proved to be less safe, except in well-deﬁned patients with regular
urological follow-up [105].
In patients with poor hand function and urinary incontinence,
use of an external appliance to collect urine is feasible. Long-term
indwelling catheters should be avoided, except for patients with
tetraplegia and those who are bedbound, in whom an indwelling
urethral Foley catheter or suprapubic cystostomy may be an alter-
native [90,106e109]. In addition, in hospitals with the required
facilities, lower urinary tract rehabilitation including behavioral
modiﬁcation, pelvic ﬂoor muscle exercises, pelvic ﬂoor electro-
stimulation, or biofeedback may be provided to patients who have
incomplete lesions and retained lower urinary tract function, such
as those with MS [110e114].
12.2. Intermittent catheterization
Intermittent catheterization (IC) is the standard treatment for
patients who are unable to empty the bladder [102,103,115]. Pa-
tients should be well instructed regarding the technique and risks
of IC. Aseptic IC is the method of choice. The optimal catheter size is
12e14 Fr. The bladder volume must remain below 400 mL, and the
post-IC residual should be low. Insufﬁcient patient education and
the inherent risk of UTI in patients with NLUTD are contributing
factors for poor outcomes [115,116]. The average frequency of
catheterizations is four to six times per day. Less frequent cathe-
terization results in higher catheterization volumes and a higher
risk of UTI. More frequent catheterizations increase the risk of cross
infections and other complications [115,117,118].
Indwelling transurethral and suprapubic catheterization should
be performed only exceptionally and under close control, and thecatheter should be changed frequently. Silicone catheters are
preferred and should be changed every 2e4 weeks. Latex catheters
(coated) need to be changed every 1e2 weeks [106,109].
13. Drug treatment of NLUTD
DO can be treated effectively with anticholinergics (oxybutynin,
tolterodine, trospium, and propiverine) [119e125]. These drugs
have diverse tolerance proﬁles, and if a patient experiences adverse
effects from one drug, another may be prescribed [126]. The long-
term efﬁcacy and safety of antimuscarinic therapy for NDO is well
documented. A combination of antimuscarinic agents is now used
more frequently and is often considered to maximize outcomes for
NDO. Alternative methods of administration of antimuscarinic
agents, such as transdermally and intravesically, should be
considered in refractory cases [127]. In one study in 21 patients
with NDO (17 with SCI), the use of tolterodine (4 mg twice daily)
and trospium chloride (30 mg 3 times daily) at higher than rec-
ommended doses was found to be an effective therapeutic strategy,
which improved bladder urodynamic parameters and was not
associated with a signiﬁcant increase in side effects compared with
standard dosages [128].
Therapy with drugs to improve detrusor contractility has not
been successful. Oral bethanechol can increase intravesical tone
and facilitate bladder emptying by abdominal straining in patients
who respond to electromotive intravesical bethanechol testing
[129].
Alpha-blockers (terazosin and alfulzosin) and skeletal muscle
relaxants (baclofen and diazepam) have been partly successful in
decreasing bladder outlet resistance [130e133]. A nitric oxide
donor has been shown to be effective in reducing bladder outlet
resistance in experimental use [134]. There is a lack of prospective,
randomized, controlled studies on the medical management of
NLUTD. Increased bladder outlet resistance may be achieved by
adrenoceptor agonists.
Because patients with NLUTD may have both storage and
emptying LUTSs, a combination medication can be used to improve
bladder storage and facilitate bladder emptying. To treat inconti-
nence, a combination therapy with anticholinergics and adrenergic
agonists (methylephedrine) with CIC is needed. However, careful
monitoring of the PVR and any UTIs is necessary. To facilitate
voiding, a combination of a cholinergic agent, an alpha-blocker, and
a skeletal muscle relaxant can be used. However, urinary inconti-
nence might be exacerbated, and the risk of upper tract deterio-
ration might be increased if the DLPP is high.
NDO is commonly treated by antimuscarinics [135], bladder
neck dysfunction by alpha-blockers, and striated sphincter spas-
ticity by skeletal muscle relaxants or nitric oxide donors [134].
Detrusor muscle tone can be increased by cholinergic agents such
as bethanechol. These agents are commonly prescribed to achieve
better bladder control or efﬁcient emptying [129]. However, NLUTD
may not be controlled without combined medications for detrusor
dysfunction and bladder outlet resistance. A combination of alpha-
adrenergic blockers and antimuscarinic agents is expected to be
more beneﬁcial than either of these for the treatment of voiding
dysfunction [136]. Addition of desmopressin may improve the ef-
ﬁcacy of the treatment [137]. However, adverse effects increase
with the use of multiple medications. Therefore, intravesical
treatment of NLUTD is a possible future treatment strategy for DO.
13.1. Intravesical treatment of NDO
Intravesical instillation of capsaicin or resiniferatoxin can suc-
cessfully eradicate incontinence due to DO and can be considered a
second-line treatment for NVD [138e140]. After a single
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and urinary continence improved for 3e6 months. Patients treated
with intravesical instillation of resiniferatoxin fared better than
those treated with capsaicin, mainly because of less irritation and
durable effects. For the treatment of high-level SCI and DSD, a dose
of 10mM was necessary to achieve good therapeutic results. How-
ever, the high concentration of intravesical vanilloid may induce AD
during intravesical instillation, which has limited this treatment to
the clinical trial stage [141].13.2. Neurotoxin bladder and urethral injections
The treatment strategy for NLUTD should include less invasive
and reversible procedures such as neurotoxin injection into the
detrusor or urethral sphincter for bladder control and emptying.
Intravesical botulinum toxin-A (BoNT-A; Botox or Dysport) injec-
tion has been demonstrated to be effective in restoration of urinary
continence and remains durable for up to 9 months [142e144].
Detrusor BoNT-A injection increases bladder capacity and de-
creases intravesical pressure. Doses of 200 U and 300 U were found
to have the same therapeutic effects on NDO, and 200 U has been
approved by the US Food and Drug Administration [145]. This
treatment is also effective in treating children with myelome-
ningocele with detrusor hyperreﬂexia and incontinence [146,147].
Repeat BoNT-A detrusor injections seem to be as effective as the
ﬁrst injection [148]. In one study, BoNT-A was signiﬁcantly more
effective in reducing the maximum pressure of uninhibited
detrusor contractions than resiniferatoxin at all follow-up time
points [149]. Urethral BoNT-A injection reduces urethral resistance
in patients with DSD and DA [150], and an early return of detrusor
contractility seems possible in patients with urethral sphincter
pseudodyssynergia due to CVAs or PD [151].
In 2011, detrusor injection of 200 U onabotulinumtoxinA was
approved by the United States Food and Drug Administration for
the treatment of NDO due to SCI and MS. Detrusor injections of
200e300 U of onabotulinumtoxinA can reduce detrusor contrac-
tility, improve bladder compliance, and restore urinary continence
in patients with NDO [142,152,153]. However, clinically, this treat-
ment usually induces impaired detrusor contractility, a large PVR,
or urinary retention in patients with NDO. About 70% of patients
require periodic CIC, and subsequent UTI could become a de novo
problem [154].
BoNT-A toxin treatment of DO due to spinal cord lesion has been
reported to provide satisfactory results [155,156]. DU develops after
detrusor injection of 300 U of onabotulinumtoxinA, and improve-
ment in the urodynamic and QoL parameters last for 9 months
[157]. Seventy-three percent of patients with neurogenic bladder
can return to continence after treatment [154]. Recent studies
further revealed that an injection of 100 U of onabotulinumtoxinA
intradetrusor for MS seems to be effective and safe. Most patients
can void voluntarily without compromising voiding efﬁciency
[76,158]. In patients with PD and refractory DO, intradetrusor in-
jection of 100 U of onabotulinumtoxinA also induced clinical and
urodynamic improvement in overactive bladder, which lasted for 6
months [159,160].
Recent randomized, double-blind, placebo control trials of
BoNT-A on NDO revealed that BoNT-A has beneﬁts in both SCI and
MS patients with NDO. BoNT-A signiﬁcantly reduced urinary in-
continence and improved urodynamic parameters and QoL in MS
and SCI patients with NDO. Doses of both 200 U and 300 U of
onabotulinumtoxinA were well tolerated, with no clinically rele-
vant differences in efﬁcacy or duration of effect [145]. Interestingly,
BoNT-A injections for NDO that included the trigone were found to
have signiﬁcant superiority in treating both incontinence episodesand urodynamic parameters compared with injections that spared
the trigone [161].
13.3. Urethral or detrusor BoNT-A injections for DSD?
Patients with DSD usually have both storage and emptying
symptoms. Some patients with DSD must have CIC performed by
themselves or caregivers, in addition to voiding by abdominal
tapping. However, some patients with DSD prefer spontaneous
voiding without instituting CIC and some might prefer being dry
after treatment even if CIC is necessary. Therefore, management of
voiding dysfunction and incontinence in patients with SCI and DSD
is a challenge for physicians, and should be considered an art.
About 95% of patients with suprasacral lesions demonstrate DO
with or without DSD [59]. Hand dexterity, abdominal muscle po-
wer, bladder sensation, and the degree of urethral sphincter dys-
synergia might affect voiding efﬁciency and LUTD. Urethral BoNT-A
injections can reduce urethral resistance [67,150]. Combined
detrusor and urethral BoNT-A injections can achieve the desired
goals [155]. Reduction of DO can decrease urinary incontinence,
whereas reduction of urethral resistance can decrease the PVR.
Although intradetrusor BoNT-A injections for NDO can increase
bladder capacity and achieve urinary continence, CIC is still
required. This management is rational but might not be adopted
widely in developing countries where public services for CIC are
lacking. Patients who do not have facilities or resources for CIC may
prefer spontaneous voiding and wearing an external appliance
without using CIC. To improve incontinence, decrease urgency
episodes, and retain spontaneous voiding function, a lower dose of
BoNT-A for detrusor injections may provide satisfactory results for
the majority of patients with spinal cord lesions and DSD [162].
Treatment of NDO and DSD may also be different between
genders. Female patients with SCI and DSD usually have more se-
vere urinary incontinence and need diaper protection. CIC requires
more facilities and resources for women, so women with SCI and
DSD may prefer to be dry and get rid of diapers. By contrast, male
SCI patients can use an external appliance to collect urine and
prevent urine soiling. Therefore, the desire to become dry is not as
great as that in females. Nevertheless, male SCI patients may not
appreciate being completely dry and may need CIC after detrusor
BoNT-A injection. In that case, a small dose of BoNT-A, e.g., 200 U of
onabotulinumtoxinA, would be adequate to increase bladder ca-
pacity and allow patients to void by abdominal tapping [163].
There are several important issues that physician should know
prior to performing BoNT-A injections in patients with NDO: (1)
behavioral modiﬁcation should be the ﬁrst management; (2) BoNT-
A injections should be given to patients after antimuscarinics fail or
there are intolerable adverse events; (3) CIC is necessary for most
patients who respond to BoNT-A; (4) monitoring the PVR and
subsequent UTI is necessary; (5) monitoring the upper urinary tract
(by renal sonography or glomerular ﬁltration rate) is important; (6)
repeated BoNT-A injections are necessary to maintain the desired
therapeutic effect; and (7) patients with urethral strictures, those
who are unwilling to perform CIC, and those with failure after the
ﬁrst treatment should not receive this therapy.
13.4. Renal function preservation
Renal function is also an important issue in the management of
NVD, especially in chronic SCI patients. Patients with DSD, a low
compliant bladder, and high intravesical pressure at end-bladder
ﬁlling may be at high risk of renal failure. The incidence of
chronic renal disease in patients with paraplegia and neural tube
defects is higher than that in the healthy population [164]. Bladder
management affects bladder compliance, and compliance changes
H.-C. Kuo et al. / Tzu Chi Medical Journal 26 (2014) 103e113 109with time. Patients using IC have a signiﬁcantly higher incidence of
normal compliance than those with Foley management. Low
bladder compliance is statistically associated with VUR, radio-
graphic upper tract abnormality, pyelonephritis, and upper tract
stones. CIC is a superior method for preserving bladder compliance
and preventing upper tract complications associated with low
compliance [165]. Patients with DSD who are currently using an
indwelling catheter, performing CIC, or voiding spontaneously
should be monitored annually to prevent renal failure. Oral anti-
muscarinic agents or intravesical Botox injections might provide a
low-pressure bladder and preserve renal function in the long-term
management of NLUTD.
13.5. AD and UTI in SCI
AD is a potentially life-threatening condition and occurs most
often in individuals with SCI above the T6 level [166]. It is charac-
terized by severe paroxysmal hypertension (episodic high blood
pressure) associated with throbbing headaches, profuse sweating,
nasal stufﬁness, ﬂushing of the skin above the level of the lesion,
bradycardia, apprehension, and anxiety, which are sometimes
accompanied by cognitive impairment [167]. Patients with chronic
SCI may develop AD during bladder overdistention, stool impac-
tion, or UTI.
The most common causes of AD are bladder distention and stool
impaction. UTI can also trigger AD regardless of whether there is an
indwelling catheter or not. In spinal cord transection, these afferent
impulses are unable to travel past the injury, resulting in an
enhanced spinal cord reﬂex to the autonomic nervous system in
response to stimuli. It is believed that these afferent stimuli trigger
and maintain an increase in blood pressure via sympathetically
mediated vasoconstriction in the muscle, skin, and splanchnic
vascular beds [168].
The incidence of AD in patients with SCI above T6 ranges from
19% to 70%. Patients with DSD have a higher incidence of AD. Alpha-
blockers or detrusor BoNT-A injections have been proved to be able
to alleviate AD.
Febrile UTI should be treated with adequate antibiotics, ac-
cording to the results of urine culture. No treatment is necessary for
asymptomatic bacteriuria. Urodynamic study is indicated in pa-
tients with recurrent UTI. When high intravesical pressure, large
PVR, VUR, contracted bladder, or other lower urinary tract abnor-
malities are detected, medication or a surgical intervention to
lower intravesical pressure or increase bladder capacity, or an
antireﬂux procedure should be instituted.
13.6. Surgical management of NVD
For patients without therapeutic effects after medical treatment
or intravesical vanilloid instillation, surgical intervention is
mandatory to treat urological complications and preserve renal
function.
Transurethral external sphincterotomy provides signiﬁcant
reduction of voiding pressure and AD in male SCI patients. The high
systolic and diastolic blood pressure as well as PVR will decrease
after sphincterotomy [169]. Transurethral incision of the bladder
neck can also reduce AD and facilitate spontaneous voiding in pa-
tients with incomplete cervical SCI [170]. In tetraplegic patients, a
urethral stent implant can relieve urethral resistance and facilitate
spontaneous voiding. However, the patient should be monitored
for possible stent migration. The most frequent stent complication
is displacement, followed by stenosis, lithiasis, and intraprosthetic
calciﬁcation. In all, 8.5% of patients require stent removal [171].
Bladder augmentation either by a segment of intestine [94] or
autoaugmentation using myomectomy [172] can result in a large-capacity, low-intravesical-pressure, and nonreﬂux condition. Most
patients reported no signiﬁcant change in bowel function, and
nearly all patients expressed extreme satisfaction with urological
management [173]. However, long-term complications, such as
stone formation, loose stools, metabolic acidosis, and chronic UTI,
remain [174]. In patients with cervical SCI or severe urethral
sphincter deﬁciency, continent lower urinary tract reconstruction
(such as a Kock pouch) or closure of the bladder neck plus continent
ileostomy and bladder augmentation may provide a chance to
become continent and evacuate the bladder by CIC from an ileos-
toma [175].
Other surgical treatments for NLUTD to increase bladder ca-
pacity and improve storage function include urethral and bladder
neck procedures: urethral sling, artiﬁcial urinary sphincter [176],
functional sphincter augmentation, bladder neck and urethra
reconstruction (YoungeDeeseLeadbetter procedure) [177], detru-
sor myectomy (autoaugmentation), denervation, deafferentation,
neurostimulation, neuromodulation: sacral rhizotomy and sacral
anterior root stimulation, bladder covering by striated muscle, and
urinary diversion [94].
13.7. Treatment of VUR
Ureteral reimplantation has an immediate and long-lasting
result in over 90% of patients [178,179]. Subtrigonal injections of
bulking agents may be tried ﬁrst in patients with NLUTD and VUR
[180]. Ureteral reimplantation alone or combined with bladder
augmentation in patients with contracted bladder are effective
procedures in patients with failed initial injection procedures [181].
When treating VUR, the physician should consider lowering the
intravesical pressure at the same time [182]. The relative risks of
more invasive and less successful therapies should be considered
ﬁrst.
14. QoL issues
QoL is also important in the treatment strategy for NVD. Pa-
tients' agreement with the management modality, their hand
function and capability for self-care, and social, economic, and
family support should be taken into consideration. Intravesical
BoNT-A injection provides great satisfaction to patients with
neurogenic DO [183]. However, > 70% of patients need CIC to
evacuate their bladder [154]. This treatment may not be accepted
by patients in Asian countries, as their environment and social
support are not as good as those in western countries [162]. When
performing BoNT-A injections for patients with DSD, injecting into
the detrusor or urethra should be evaluated carefully prior to
treatment. An unpublished study comparing SCI patients receiving
intravesical BoNT-Awith those receiving urethral sphincter BoNT-A
showed that the intravesical group had more improvement in QoL
than the urethral group. When considering the needs of patients
with NLUTD, either a reduced dose of BoNT-A or a combination of
detrusor and urethral BoNT-A injections may provide better ther-
apeutic satisfaction in patients who wish to preserve spontaneous
voiding and become less incontinent.
15. Rational treatment strategy for NVD
Bladder and urethral dysfunction changes with time in patients
with NLUTD. These patients should be followed up regularly for
lower urinary tract dysfunction, and any urological complication
should be treated adequately. Avoiding a chronic indwelling cath-
eter can reduce the incidence of developing a low compliant
bladder. Long-term antimuscarinic therapy can decrease urinary
incontinence and lower intravesical pressure. Intravesical
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treatments for refractory DO or a low compliant bladder, and can
replace the need for bladder augmentation. When surgical inter-
vention is necessary, less invasive types of surgery and reversible
procedures should be considered ﬁrst, and any unnecessary surgery
in the lower urinary tract should be avoided. Keeping the bladder
and urethra in good condition without the interference of neuro-
muscular continuity provides patients with NVD a chance to try
new technologies in the future. Improving the QoL in patients with
NVD is the most important aspect of treatment.
16. Future technologies
Many novel therapeutic trials of treatments for SCI and NLUTD
have been conducted in recent decades. Repair of spinal cord
trauma by nerve grafts and stabilization of the grafted area with
ﬁbrin glue containing acid ﬁbroblast growth factor have been
successful in treating chronic paraplegia [184]. Transplants of ﬁ-
broblasts expressing brain-derived nerve growth factor and
neurotrophin-3 have been applied in an animal SCI model and
found to improve both bladder and hindlimb function, which was
associated with reorganization of spinal circuitry [185]. Trans-
plantation of immortalized neural stem cells into the injured spinal
cord could promote recovery of voiding function in rats [186].
Direct re-establishment of a somatoautonomic reﬂex pathway to
reinnervate the neurogenic bladder has been successful in children
withmyelodysplasia [187]. Nerve crossover surgery in a neurogenic
bladder by cutting the proximal portion of the S2eS3 roots and
end-to-end anastomosis to the intercostal nerves can restore cen-
tral connections to the bladder [188]. Using intermittent electrical
stimulation of the pudendal nerve or sacral anterior root stimula-
tion can provide alternative treatments for DA and DSD [189e191].
The use of bladder acellular matrix grafts may be a choice for
bladder augmentation to improve bladder capacity in SCI-induced
neurogenic bladder [192,193]. All these technical advancements
show that NVD could be treated adequately in the future.
17. Guidelines for follow-up
Although patients with LUTD may be properly diagnosed and
treated, all patients should receive life-long surveillance to prevent
the development of urological complications and undesired LUTSs
[60,194,195]. The following procedures are important in long-term
follow-up: (1) possible UTI checked by the patient (dipstick); (2)
urinalysis every 2nd month; (3) assessment of the upper urinary
tract, bladder morphology, and PVR every 6 months (by ultra-
sound); (4) physical examination, blood chemistry, and urine lab-
oratory tests every year; (5) detailed investigation by a specialist
every 1e2 years and on demand when risk factors emerge. The
investigation is speciﬁed according to the patient's actual risk
proﬁle, but should in any case include a videourodynamic investi-
gation and be performed in a leading neurourological center.; and
(6) more frequent investigations in high-risk patients or if
demanded by the neurological pathology or the NLUTD status.
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